CBD Effects on Fatty Liver: Risks and Evidence

CBD effects on fatty liver disease are a growing area of interest, particularly as metabolic dysfunction-associated steatotic liver disease (MASLD) becomes increasingly common in the UK. With no medicines currently licensed specifically for MASLD, some people are turning to cannabidiol (CBD) supplements as a complementary option. However, the evidence base remains largely preclinical, and there are genuine safety considerations for anyone with a liver condition. This article examines what the research shows, the potential risks of CBD use in liver disease, and why speaking to your GP before starting any supplement is essential.

What is fatty liver disease and how common is it in the UK?

Fatty liver disease, particularly MASLD, is one of the most prevalent chronic liver conditions in the UK, closely linked to obesity, type 2 diabetes and insulin resistance, with no medicines currently licensed specifically for its treatment.

Fatty liver disease is one of the most prevalent chronic liver conditions in the UK. It occurs when excess fat accumulates within liver cells, impairing normal function over time. There are two principal forms: alcohol-related fatty liver disease (ARLD), linked to heavy or prolonged alcohol consumption, and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD), which is closely associated with obesity, type 2 diabetes, raised cholesterol and insulin resistance.

MASLD has grown significantly alongside rising rates of obesity and metabolic syndrome in the UK. NHS and British Liver Trust estimates suggest MASLD affects a substantial proportion of the general adult population, with a subset progressing to more serious stages including metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), fibrosis and, in some cases, cirrhosis or liver cancer. Readers will still encounter the older terms NAFLD and NASH on many NHS and NICE pages; MASLD and MASH are the current internationally agreed terms.

Many people with early fatty liver disease have no symptoms, which means the condition often goes undetected until it is identified incidentally during an ultrasound or blood test. In UK primary care, GPs use a scoring tool called FIB-4 (which takes into account age, liver enzyme levels and platelet count) to assess the likelihood of significant liver fibrosis. Depending on the result, further testing such as the Enhanced Liver Fibrosis (ELF) blood test or referral to a hepatologist may follow. NICE guidance (NG49) sets out these referral thresholds.

If you experience any of the following, seek prompt medical attention as they may indicate more advanced liver disease: yellowing of the skin or eyes (jaundice), swelling of the abdomen, confusion or difficulty thinking clearly, or vomiting blood or passing black tarry stools. These require urgent assessment.

NICE guidance recommends lifestyle modification, including weight loss, improved diet and increased physical activity, as the cornerstone of management. There are currently no medicines specifically licensed in the UK for MASLD, which has led some individuals to explore complementary options, including cannabidiol (CBD). Understanding the evidence and risks around such approaches is important before making any changes to a management plan.

What does current research say about CBD and liver health?

Research on CBD and fatty liver disease is largely preclinical; animal studies suggest potential benefits, but no robust human clinical trials support recommending CBD as a treatment for any liver condition.

Current research on CBD and fatty liver disease is at an early, largely preclinical stage, and no firm conclusions can be drawn about its benefit or safety in humans with liver conditions. CBD (cannabidiol) is a non-intoxicating compound derived from the cannabis plant. It interacts with the endocannabinoid system, which plays a role in regulating metabolism, inflammation and lipid processing, all of which are relevant to fatty liver disease.

Animal studies, primarily in rodent models, have suggested that CBD may reduce hepatic fat accumulation, oxidative stress and inflammatory markers associated with MASLD. Some laboratory research has indicated that CBD may influence CB1 and CB2 receptor activity in liver tissue, potentially modulating fibrotic and inflammatory pathways. However, these findings have not been reliably replicated in robust human clinical trials. The human evidence base remains limited by small sample sizes, variable methodologies and inconsistent results.

It is important to distinguish between two very different categories of CBD product in the UK. Over-the-counter CBD supplements are regulated as novel foods by the Food Standards Agency (FSA), not as medicines, and are not authorised to treat any medical condition.^[4][5] Epidyolex is a separately licensed CBD medicine authorised by the MHRA for specific, severe forms of epilepsy only; its licence does not extend to liver disease.^[7][8] Neither the MHRA nor the European Medicines Agency (EMA) has authorised any CBD product for the treatment or management of fatty liver disease.

The FSA advises that healthy adults should not exceed 10 mg of CBD per day from food supplements.^[4][6] The FSA also advises that CBD supplements should be avoided by people who are pregnant, breastfeeding or trying to conceive, and should not be given to anyone under 18 years of age.^[6] People taking prescribed medicines should seek advice from their GP or pharmacist before using CBD, as interactions are possible.

Researchers continue to investigate the endocannabinoid system as a therapeutic target in liver disease, but at present the evidence base is insufficient to support recommending CBD as a treatment for fatty liver disease. Patients should be cautious about interpreting preclinical data as applicable to their own health decisions.

Could CBD make fatty liver disease worse?

CBD can potentially worsen liver health, particularly at higher doses or in people with compromised liver function, as it is hepatically metabolised and has been associated with elevated liver enzymes in clinical trial data.

CBD could potentially worsen liver health in certain circumstances, particularly at higher doses or when taken alongside other substances that the liver processes. This is not a theoretical concern: the liver is the primary site of CBD metabolism, and there is documented evidence from clinical studies of Epidyolex (the licensed high-dose CBD medicine) that elevated liver enzymes can occur, particularly at higher doses. This hepatotoxicity signal is described in the Epidyolex Summary of Product Characteristics (SmPC) and the EMA's European Public Assessment Report. It is worth noting that the doses used in clinical trials of Epidyolex are considerably higher than those found in over-the-counter CBD supplements; however, the threshold for harm in individuals with pre-existing liver disease may be lower than in healthy individuals, so caution is warranted even at lower doses.

For someone who already has compromised liver function due to fatty liver disease, fibrosis or cirrhosis, the liver's capacity to metabolise CBD may be reduced. This could lead to higher circulating levels of CBD and a greater risk of adverse effects.

CBD also inhibits several cytochrome P450 enzymes, including CYP3A4, CYP2C9 and CYP2C19, as well as UGT enzymes (such as UGT1A9 and UGT2B7), which are responsible for metabolising a wide range of medicines.^[10] This means CBD can alter the effectiveness or toxicity of other drugs a person is taking. The interaction with some anticoagulants (such as warfarin), antiepileptics (such as valproate and clobazam) and certain other medicines is clinically relevant.^[10][11] The effect on statins varies: only some statins are significantly metabolised by CYP3A4 (for example, atorvastatin and simvastatin), while others are less affected.^[12] Anyone taking prescribed medicines should discuss potential interactions with their GP or pharmacist before using CBD.

There is also a concern that some commercially available CBD products may contain contaminants, inconsistent concentrations or undisclosed additives, including traces of tetrahydrocannabinol (THC). The FSA has noted that the quality and labelling of CBD food supplements in the UK varies considerably, and some products have been found to contain levels of THC or CBD that differ from label claims.^[4][5]

Heavy or chronic alcohol use combined with CBD use has not been well studied in humans, but given that both are hepatically metabolised, the combination warrants particular caution. Anyone with a diagnosed liver condition should not assume that a natural or supplement-based product is automatically safe.

What are the safety risks of taking CBD with a liver condition?

Key risks include hepatotoxicity, clinically significant drug interactions via CYP450 enzyme inhibition, variable product quality, and increased hepatic burden when combined with alcohol or other liver-metabolised substances.

Taking CBD with a liver condition carries several safety considerations that patients and clinicians should be aware of before use. The most clinically significant risk is hepatotoxicity, which refers to liver damage caused or worsened by a substance. The clearest evidence for CBD-associated liver enzyme elevations comes from high-dose clinical trial data for Epidyolex; the risk at the lower doses found in over-the-counter supplements is less well characterised, but individuals with pre-existing liver disease may be more vulnerable.

Key safety risks include:

• Drug interactions: CBD can inhibit liver enzymes (CYP3A4, CYP2C9, CYP2C19 and UGT enzymes) responsible for metabolising anticoagulants (such as warfarin), certain antiepileptics (such as valproate and clobazam), some statins and other commonly prescribed medicines, potentially increasing their concentration and risk of side effects. A medicines review with your GP or pharmacist is advisable before starting CBD.

• Liver enzyme elevation: Clinical data from Epidyolex trials show raised alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels, particularly at higher doses. If CBD is used at all in the context of liver disease, baseline liver function tests and follow-up monitoring at one to three months are advisable, and only after clinician review.

• Product quality variability: Many CBD supplements sold in the UK have not undergone the rigorous testing required of licensed medicines, meaning the actual dose and purity may differ from what is stated on the label. The FSA advises healthy adults not to exceed 10 mg of CBD per day from food supplements.^[4][6]

• Populations who should avoid CBD: The FSA advises that CBD supplements should not be used by people who are pregnant, breastfeeding or trying to conceive, and should not be given to anyone under 18 years of age.^[6]

• Cumulative hepatic load: Combining CBD with alcohol or other hepatically metabolised substances may increase the overall burden on a compromised liver. The evidence for specific combinations such as CBD with paracetamol is limited in humans, but the theoretical concern is sufficient to warrant caution.

If you are taking CBD and notice symptoms such as persistent nausea, loss of appetite, yellowing of the skin or eyes (jaundice), dark urine or upper abdominal discomfort, contact your GP promptly. These may indicate liver stress and require investigation. Suspected adverse reactions to CBD products can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[13][14]mhra.gov.uk.

Should you talk to your GP before using CBD for liver health?

Yes, anyone with a liver condition or risk factors for fatty liver disease should consult their GP before using CBD, as it is not a licensed treatment and may interact with prescribed medicines or worsen liver function.

Yes, anyone with a diagnosed liver condition, or risk factors for fatty liver disease, should speak to their GP before starting CBD. This is particularly important because CBD is not a licensed treatment for any liver condition in the UK, and its interaction with liver function and prescribed medicines means it cannot be considered risk-free, even in supplement form.

Your GP can review your current liver function tests, assess any medicines you are taking that might interact with CBD, and advise whether use is appropriate given your individual health profile. In UK primary care, GPs use the FIB-4 score to assess fibrosis risk, with age-adjusted cut-off values guiding whether further testing (such as the ELF test) or referral to a hepatologist is needed. NICE guidance (NG49) sets out these pathways. Any complementary approach, including CBD, should be discussed within that framework rather than pursued independently.

If you are considering a weight management programme that includes medical review, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, as part of a broader range of options available to patients.

For those managing fatty liver disease, the most evidence-based steps remain weight reduction, a balanced diet low in refined sugars and saturated fats, regular physical activity and avoidance of alcohol. NICE NG49 and EASL 2024 MASLD guidelines indicate that a reduction in body weight of around 7 to 10 per cent is associated with meaningful improvements in hepatic fat and, in some cases, resolution of MASH; even more modest weight loss can reduce hepatic fat to some degree. These lifestyle interventions have a far stronger evidence base than any supplement currently available. If you are unsure whether CBD is safe for you, your GP or a pharmacist registered with the General Pharmaceutical Council (GPhC) can provide personalised guidance based on your medical history.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): NICE guideline NG49.
2. Metabolic dysfunction-associated steatotic liver disease (MASLD): recommendations for research – NG49.
3. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis – NICE MIB317.
4. Cannabidiol (CBD) guidance – Food Standards Agency.
5. CBD products linked to novel food applications – Food Standards Agency.
6. CBD novel food applications: recommendations to ministers on first authorisations – Food Standards Agency.
7. Advice on Epidyolex (accessible version) – MHRA.
8. Epidyolex: European Public Assessment Report (EPAR) – European Medicines Agency.
9. Epidyolex: Patient Information Leaflet – Electronic Medicines Compendium.
10. Cannabidiol: Interactions – BNF/NICE.
11. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Cannabidiol and Clobazam, Stiripentol, or Valproate in Healthy Subjects – Wheless JW et al..
12. An updated review of pharmacokinetic drug interactions with statins and CYP3A4 inhibitors – Hirota T et al..
13. Adverse reactions to drugs: Yellow Card scheme – BNF/NICE.
14. Herbal medicines: report suspected adverse reactions to the Yellow Card scheme – MHRA Drug Safety Update.

Frequently Asked Questions